You are viewing: China Neuromodulation Market analysis
Part of: Neuromodulation Market (Global)

The China Neuromodulation Market was valued at $377 Million in 2025 and projected to reach to $752 Million by 2030, representing a compound annual growth rate of 14.8%. China's neuromodulation market is positioned for exceptional growth, expanding from $377.0 million in 2025 to $752.0 million by 2030.

China Neuromodulation Market Trends and Insights

  • This accelerated growth in China significantly outpaces the global neuromodulation market CAGR of 9.4%, reflecting the country's rising healthcare investments and aging population.
  • China's rapid urbanization, increasing prevalence of neurological disorders, and expanding access to advanced medical technologies are driving demand for neuromodulation therapies across pain management, movement disorders, and psychiatric applications. The neuromodulation sector in China is benefiting from government healthcare reforms and enhanced reimbursement policies that improve patient access to innovative treatments.
  • China's growing middle class and rising healthcare expenditure are creating favorable conditions for market penetration of both established and emerging neuromodulation devices.
  • As China continues to strengthen its medical device manufacturing capabilities and regulatory frameworks, the country is positioned to become a key growth engine within the Asia Pacific neuromodulation market through 2030..

Key Market Statistics

  • CAGR (2025-2030) 14.8% CAGR
  • Market Size, 2025 ~USD 377 Million
  • Forecast, 2030 ~USD 752 Million
  • Country China

China Neuromodulation Market Overview

Fastest Growing Market Globally :

China's neuromodulation market CAGR of 14.8% significantly exceeds the global average of 9.4%, driven by increased healthcare spending and government support for advanced medical technologies.

Aging Population Catalyst :

China's rapidly aging demographic is driving demand for neuromodulation therapies to treat neurological disorders, chronic pain, and movement disorders, creating substantial market opportunities.

Urbanization & Healthcare Access :

Rapid urbanization in China is expanding access to advanced neuromodulation treatments in tier-1 and tier-2 cities, with improving healthcare infrastructure and rising disposable incomes.

Government Investment & Reimbursement :

Increased government healthcare investments and expanding insurance coverage for neuromodulation procedures are reducing patient barriers and accelerating market penetration across China.

China Neuromodulation Market Dynamics

  • This trajectory reflects structural tailwinds including an aging population exceeding 280 million individuals, rising prevalence of neurological conditions, and substantial government healthcare modernization initiatives.
  • The market benefits from improving reimbursement policies and increasing adoption of advanced technologies in major urban centers. Looking ahead, China's neuromodulation sector will be shaped by domestic innovation, regulatory streamlining, and growing patient awareness.
  • Key drivers include expanding middle-class purchasing power, integration of neuromodulation into standard clinical practice, and development of cost-effective solutions tailored to the Chinese market.
  • Strategic partnerships between international manufacturers and local healthcare providers will accelerate market penetration and technology adoption across the country..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • China's neuromodulation market is projected to double from $377.0M (2025) to $752.0M (2030) at a 14.8% CAGR, outpacing global growth.
      • China's aging population and rising neurological disease burden are primary drivers of neuromodulation adoption across pain, movement, and psychiatric indications.
      • Government healthcare reforms and improved reimbursement policies in China are expanding patient access to neuromodulation therapies.
      • China's strengthening medical device manufacturing and regulatory capabilities position it as a critical growth market within Asia Pacific through 2030.

      Neuromodulation Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment DEEP BRAIN STIMULATION (Stimulation Type)
      Forecast Period 2025–2030
      Growth Rate CAGR of 9.4% from 2025 to 2030
      Largest Segment INTERNAL NEUROMODULATION (Technology)
      Market Size Base Year (Billions) ~USD 6.82 (2025)
      Revenue Forecast (Billions) ~USD 10.68 (2030)
      Segments Covered Technology, Stimulation Type, Application, End User

      China Neuromodulation Market Report Segmentation

      4 segment dimensions are covered across the global market.

      By Technology

      • External Neuromodulation
      • Internal Neuromodulation

      By Stimulation Type

      • Deep Brain Stimulation
      • Gastric Electrical Stimulation
      • Other Stimulation Types
      • Respiratory Electrical Stimulation
      • Sacral Nerve Stimulation
      • Spinal Cord Stimulation
      • Transcranial Magnetic Stimulation
      • Transcutaneous Electrical Nerve Stimulation
      • Vagus Nerve Stimulation

      By Application

      • Chronic Pain
      • Depression
      • Epilepsy
      • Failed Back Surgery Syndrome
      • Fecal Incontinence
      • Gastroparesis
      • Ischemia
      • Migraine
      • Obesity
      • Other Deep Brain Stimulation Applications
      • Other Transcutaneous Electrical Nerve Stimulation Applications
      • Other Vagus Nerve Stimulation Applications
      • Parkinson’S Disease
      • Treatment-Resistant Depression
      • Tremor
      • Urine Incontinence

      By End User

      • Clinics & Physiotherapy Centers
      • Hospitals & Ambulatory Surgery Centers
      • Other End Users

      Target Audience

      • Medical Device Manufacturers : Neuromodulation device companies need China-specific market data to evaluate expansion opportunities, assess competitive positioning, and develop localized product strategies in this high-growth market.
      • Healthcare Investors & PE Firms : Investment professionals require detailed China market analysis to identify acquisition targets, evaluate portfolio company growth potential, and make informed capital allocation decisions in neuromodulation.
      • Hospital & Healthcare Systems : Chinese healthcare providers need market insights to justify neuromodulation program investments, understand patient demand trends, and plan service expansion in their regions.
      • Pharmaceutical & Biotech Companies : Companies developing neuromodulation-adjacent therapies require China market intelligence to identify partnership opportunities, understand treatment adoption patterns, and plan clinical development strategies.
      • Market Consultants & Analysts : Research professionals and consultants need verified China neuromodulation data to support client advisory work, competitive analysis, and strategic recommendations in the healthcare technology sector.

      Key Companies in the China Neuromodulation Market

      CompanyHQOwnershipStrongest segments
      BIOGENUnited StatesPublic CompanyInternal neuromodulation (implanted SCS/DBS/VNS-aligned adjacencies),External neuromodulation (non-invasive stimulation adjacencies),Spinal cord stimulation–linked care pathways,
      MEDTRONICIrelandPublic CompanyInternal neuromodulation – Spinal Cord Stimulation,Internal neuromodulation – Deep Brain Stimulation,Internal neuromodulation – Vagus Nerve and Other Implants,
      BOSTON SCIENTIFIC CORPORATIONUnited StatesPublic CompanyInternal neuromodulation systems (implantable SCS, DBS, VNS),External neuromodulation systems and accessories,Radiofrequency and intraosseous nerve ablation for pain,
      ABBOTTUnited StatesPublic CompanyInternal neuromodulation – Spinal cord stimulation,Internal neuromodulation – Deep brain stimulation,Internal neuromodulation – Vagus nerve and other implants,
      LIVANOVA PLCUnited KingdomPublic CompanyInternal Vagus Nerve Stimulation for Epilepsy,Internal Vagus Nerve Stimulation for Depression,Other Neuromodulation (including aura6000 OSA development),
      NEVRO CORP.United StatesPrivate CompanyInternal SCS systems (Senza, Senza II, Senza Omnia, HFX iQ IPG),Surgical and percutaneous leads,Trial stimulators, remotes, and HFX App / digital,
      NEUROPACE, INC.United StatesPublic CompanyInternal neuromodulation – Deep brain–adjacent epilepsy (RNS neurostimulator + leads),Digital platforms and data services (nSight, patient data management, physician tablet ecosystem),Accessories and disposables (non-implantable components, remote monitors, ancillary hardware),
      BIOVENTUSUnited StatesPublic CompanyExternal / Peripheral Neuromodulation (Stimrouter, TalisMann, Exogen-related pain pathways),Surgical Ultrasonic Systems (neXus, BoneScalpel, SonaStar, SonicOne) in Neuro and Spine,Bone Graft Substitutes and Restorative Therapies in Neuro/Spine Settings,
      ELECTROCORE, INC.United StatesPublic CompanyExternal VNS – gammaCore (migraine, cluster, other headache),General wellness nVNS – Truvaga 350 and Truvaga Plus,Human performance and other non-invasive bioelectronic therapies (TAC-STIM, chronic pain, performance),
      HELIUS MEDICAL TECHNOLOGIES, INC.United StatesPublic CompanyExternal neuromodulation – PoNS for gait and balance deficits,Other neurological wellness and digital programs,Other digital asset / treasury-related activities,
      NEURONETICSUnited StatesPublic CompanyExternal neuromodulation – TMS for Depression (Clinics & Psychiatrist Offices),External neuromodulation – Hospital-based TMS Programs,Other neuromodulation applications (Ischemia, Epilepsy, Obesity; emerging geographies and pilots),
      NEUROSIGMA, INC.United StatesPrivate CompanyExternal Neuromodulation – Trigeminal Nerve Stimulation (eTNS/TNS) for ADHD,External Neuromodulation – TNS for Epilepsy and LGS (early commercialization),External Neuromodulation – TNS for Depression, PTSD, TBI,

      BIOGEN

      Biogen is a United States-based biotechnology company founded in 1978 with 7,500 employees. Operating as a public company, Biogen focuses on developing and commercializing therapies for neurological and neurodegenerative diseases.

      MEDTRONIC

      Medtronic is a multinational medical device company headquartered in Ireland, founded in 1949 with 95,000 employees. As a public company, Medtronic develops and manufactures a broad range of medical devices and therapies across multiple therapeutic areas.

      BOSTON SCIENTIFIC CORPORATION

      Boston Scientific Corporation is a United States-based medical device company founded in 1979 with 59,000 employees. The public company designs, manufactures, and markets medical devices used in interventional medical specialties.

      ABBOTT

      Abbott is a diversified healthcare company founded in the United States in 1888 with 115,000 employees. Operating as a public company, Abbott develops pharmaceuticals, medical devices, diagnostics, and nutritional products.

      LIVANOVA PLC

      LivaNova PLC is a United Kingdom-based medical device company founded in 2015 with 3,300 employees. The public company specializes in neuromodulation and cardiac surgery solutions.

      NEVRO CORP.

      Nevro Corp. is a United States-based medical device company founded in 2006 with 1,099 employees. Operating as a private company, Nevro develops neuromodulation therapies for chronic pain management.

      NEUROPACE, INC.

      NeuroPace, Inc. is a United States-based medical device company founded in 1997 with 220 employees. The public company develops and commercializes neurostimulation technology for neurological disorders.

      BIOVENTUS

      BioVentus is a United States-based medical device company founded in 2011 with 940 employees. Operating as a public company, BioVentus focuses on orthopedic and regenerative medicine solutions.

      ELECTROCORE, INC.

      ElectroCore, Inc. is a United States-based bioelectronic medicine company founded in 2005 with 83 employees. The public company develops non-invasive vagus nerve stimulation therapies for various conditions.

      HELIUS MEDICAL TECHNOLOGIES, INC.

      Helius Medical Technologies, Inc. is a United States-based medical device company with 21 employees. Operating as a public company, Helius develops neurorehabilitation technologies.

      NEURONETICS

      Neuronetics is a United States-based medical device company founded in 2001 with 658 employees. The public company develops and commercializes neuromodulation therapies for psychiatric and neurological conditions.

      NEUROSIGMA, INC.

      NeuroSigma, Inc. is a United States-based neurotechnology company founded in 2008 with 11 employees. Operating as a private company, NeuroSigma develops bioelectronic therapies for neurological disorders.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Obtain precise market valuation ($377M in 2025) and verified 5-year forecast ($752M by 2030) with 14.8% CAGR to support investment decisions and business planning in China's fastest-growing neuromodulation segment.
      • Competitive Positioning Intelligence : Understand China-specific market dynamics, local competitor strategies, and regulatory landscape to identify gaps and opportunities for market entry or expansion in this high-growth region.
      • Demographic & Healthcare Trends : Access detailed analysis of China's aging population, urbanization patterns, and healthcare infrastructure development driving neuromodulation demand across different geographic and demographic segments.
      • Reimbursement & Regulatory Insights : Gain clarity on China's evolving insurance coverage, government policies, and regulatory pathways for neuromodulation devices to navigate market entry and pricing strategies effectively.
      • Strategic Growth Planning : Leverage China-specific market forecasts and trend analysis to develop targeted go-to-market strategies, partnership models, and product development roadmaps aligned with local demand drivers.

      Frequently asked questions

      What is the current size of China's neuromodulation market in 2025?

      China's neuromodulation market is valued at $377.0 million in 2025, with expectations to reach $752.0 million by 2030.

      What is the projected growth rate for neuromodulation in China?

      China's neuromodulation market is expected to grow at a compound annual growth rate (CAGR) of 14.8% from 2025 to 2030.

      How does China's neuromodulation growth compare to global trends?

      China's 14.8% CAGR significantly exceeds the global neuromodulation market CAGR of 9.4%, making China a high-growth region within the sector.

      What factors are driving neuromodulation market growth in China?

      Key drivers include China's aging population, rising prevalence of neurological disorders, government healthcare reforms, improved reimbursement policies, and expanding access to advanced medical technologies.

      What is the forecast market size for neuromodulation in China by 2030?

      China's neuromodulation market is projected to reach $752.0 million by 2030, representing a doubling of the 2025 market value.

      RESEARCH METHODOLOGY

      The study involved key activities in estimating the current market size for the neuromodulation industry. Exhaustive secondary research was conducted to gather information on the neuromodulation sector. The next step was to validate these findings, assumptions, and estimates with industry experts across the value chain through primary research. Different methods, such as top-down and bottom-up approaches, were used to determine the total market size. Subsequently, market segmentation and data triangulation procedures were applied to estimate the market size of segments and subsegments within the neuromodulation market.

      The four steps involved in estimating the market size are:

      Secondary Research

      The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, investor presentations, SEC filings of companies and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), , Global Burden of Disease Study, and Centers for Medicare and Medicaid Services (CMS) were referred to identify and collect information for the global neuromodulation market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

      Primary Research

      In the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and other key executives from various companies and organizations in the neuromodulation market. The primary sources from the demand side include biotechnology companies, CROs, pharmacies, medical device companies, and research academics and universities. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on important industry trends and key market dynamics.

      The following is a breakdown of the primary respondents:

      Neuromodulation Market

      Note 1: Others include sales managers, marketing managers, and product managers.

      Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      For the global market value, annual revenues were calculated based on revenue mapping of major product manufacturers and OEMs active in the worldwide neuromodulation market. All key service providers were identified at the global and/or country/regional level. Revenue mapping for the relevant business segments/sub-segments was performed for the major players. The global neuromodulation market was split into various segments and sub-segments based on:

      • List of major players operating in the products market at the regional and/or country level
      • Product mapping of neuromodulation providers at the regional and/or country level
      • Mapping of annual revenue generated by listed major players from neuromodulation (or the nearest reported business unit/product category)
      • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
      • Summation of the market value of all segments/subsegments to arrive at the global neuromodulation market

      The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

      The research methodology used to estimate the market size includes the following:

      Neuromodulation Market

      Data Triangulation

      After determining the overall market size using the process described above, the total market was divided into several segments. To finalize the market engineering process and obtain precise statistics for all segments and subsegments, data triangulation and market breakdown methods were employed where applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Neuromodulation is a medical technology that modifies nerve activity by delivering targeted stimulation to specific areas of the body. It covers a broad range of therapies, from managing chronic pain—which is the most common use—to treating neurological and urological disorders, as well as movement disorders like Parkinson’s disease. By directly affecting neural pathways, neuromodulation can restore function, alleviate symptoms, and enhance quality of life, with ongoing innovations making it a rapidly growing field in modern medicine healthcare.

      Stakeholders

      • Neuromodulation and related device manufacturing companies
      • Equipment manufacturers
      • Suppliers and distributors of neuromodulation devices
      • Healthcare service providers
      • Teaching hospitals and academic medical centers (AMCs)
      • Health insurance players
      • Research and consulting firms
      • Medical research institutes
      • Healthcare institutions/providers (hospitals, medical groups, physicians’ practices, diagnostic centers, and outpatient clinics)
      • Venture capitalists
      • Community centers

      Report Objectives

      • To define, describe, segment, and forecast the global neuromodulation market by technology, stimulation type, application, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall neuromodulation market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
      • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
      • To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region

      Get the Full Neuromodulation Market Report

      Full forecast, segment splits, and company analysis for all Neuromodulation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status